FDA
-
-
-
-
-
-
-
Taysha Gene Therapies (TSHA) PT Raised to $11 at Citizens on REVEAL Data Update
-
-
-
-
-
-
-
Taysha Gene Therapies (TSHA) Reiterated at Overweight by Cantor Fitzgerald on Phase 1/2 Data
-
-
-
-
-
-
-
Taysha Gene Therapies (TSHA) PT Raised to $8 at Citizens on Competitive Advantage
-
-
-
-
-
-
-
Taysha Gene Therapies (TSHA) PT Raised to $12 at Baird
-
-
-
-
-
-
-
Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program
-
-
-
-
-
-
-
7 top biotech picks for 2025 according to Wells Fargo
-
-
-
-
-
-
-
Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome
-
328,335 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

